Blueprint Medicines Corp. News Releases http://ir.blueprintmedicines.com/ Blueprint Medicines Corp. News Releases en Blueprint Medicines Announces Data Presentations at ASCO and EHA Meetings from Registration-Enabling Clinical Trials of Avapritinib and BLU-667 Across Multiple Patient Populations http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-data-presentations-asco-and-eha -- Blueprint Medicines to Host Investor Event and Webcast at ASCO on Monday, June 3, 2019 -- CAMBRIDGE, Mass. , May 16, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, Thu, 16 May 2019 09:00:00 -0400 Blueprint Medicines Corp. News Releases 9521 Blueprint Medicines Reports First Quarter 2019 Financial Results http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-reports-first-quarter-2019-financial-results -- Avapritinib NDA for PDGFRA Exon 18 mutant GIST and fourth-line GIST on track for submission to FDA in second quarter -- -- BLU-667 granted Breakthrough Therapy Designation for the treatment of RET fusion-positive NSCLC -- -- Avapritinib data in GIST and BLU-667 data in RET-altered NSCLC and MTC Thu, 09 May 2019 07:00:00 -0400 Blueprint Medicines Corp. News Releases 9501 Blueprint Medicines to Present at Bank of America Merrill Lynch 2019 Health Care Conference http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-present-bank-america-merrill-lynch-2019 CAMBRIDGE, Mass. , May 8, 2019 /PRNewswire/ --  Blueprint Medicines Corporation  (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced that Jeff Albers , Blueprint Medicines' Chief Executive Officer, will present Wed, 08 May 2019 08:00:00 -0400 Blueprint Medicines Corp. News Releases 9496 Blueprint Medicines to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019 http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-report-first-quarter-2019-financial-results CAMBRIDGE, Mass. , May 2, 2019 /PRNewswire/ --  Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webcast at 8:30 a.m. Thu, 02 May 2019 08:00:00 -0400 Blueprint Medicines Corp. News Releases 9486 Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-closing-public-offering-and-full-3 CAMBRIDGE, Mass. , April 2, 2019 /PRNewswire/ -- Blueprint Medicines Corporation  (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the closing of its previously announced underwritten public offering of Tue, 02 Apr 2019 16:01:00 -0400 Blueprint Medicines Corp. News Releases 9456 Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-pricing-public-offering-shares-3 CAMBRIDGE, Mass. , March 28, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the pricing of an underwritten public offering of 4,054,054 shares of its Thu, 28 Mar 2019 20:40:00 -0400 Blueprint Medicines Corp. News Releases 9441 Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-proposed-public-offering-shares-3 CAMBRIDGE, Mass. , March 27, 2019 /PRNewswire/ --  Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it has commenced an underwritten public offering of $300,000,000 in Wed, 27 Mar 2019 16:03:00 -0400 Blueprint Medicines Corp. News Releases 9426 Blueprint Medicines Announces Accelerated Regulatory Submission Plans and Recent Clinical Progress http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-accelerated-regulatory-submission -- Avapritinib: plan to submit MAA for PDGFRα D842V mutant GIST and fourth-line GIST in Q3 2019 and NDA for advanced systemic mastocytosis in Q1 2020 -- -- BLU-667: plan to submit NDA for previously treated RET-fusion non-small cell lung cancer in Q1 2020 based on early achievement of enrollment Wed, 27 Mar 2019 16:00:00 -0400 Blueprint Medicines Corp. News Releases 9421 Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-present-39th-annual-cowen-co-health-care CAMBRIDGE, Mass. , March 5, 2019 /PRNewswire/ --  Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced that Jeff Albers , Blueprint Medicines' Chief Executive Officer, will present Tue, 05 Mar 2019 08:01:00 -0500 Blueprint Medicines Corp. News Releases 9341 Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial Results http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-reports-fourth-quarter-and-full-year-2018 -- Avapritinib NDA for PDGFRA Exon 18 mutant GIST and fourth-line GIST on track for submission to FDA in second quarter -- -- BLU-667 receives Breakthrough Therapy Designation for the treatment of RET mutation-positive medullary thyroid cancer -- -- Continued clinical progress across the portfolio Tue, 26 Feb 2019 07:00:00 -0500 Blueprint Medicines Corp. News Releases 9316